CD4 and myeloid sarcoma: A gene expression signature that is characteristic of CD4+ cytotoxic T lymphocytes (CD4-CTLs) was found to be elevated at baseline in non-responders to apheresis, although this could not be validated with statistical significance (n=19 MS patients).